The 2026 Multi-Society Dyslipidemia Guideline represents one of the most significant paradigm shifts in cardiovascular risk management in over a decade, yet substantial practice gaps persist. Clinicians across primary care, cardiology, endocrinology, and internal medicine continue to underutilize non-statin therapies, struggle with risk stratification, and face barriers to treatment goal attainment, leaving patients at preventable risk for ASCVD events. Month 4: Non-Statin Therapies and Emerging Treatments 1. Identify when to add non-statin therapies. 2. Compare mechanisms and outcomes of newer lipid drugs. 3. Review treatment sequencing strategies. 4. Identify treatment strategies for special populations. 5. Apply guideline recommendations in high-risk populations.
Credit & MOC Details
Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.
Credit types
MOC types
FDA REMS
Qualifies for MIPS
Address:
- 6816 Southpoint Parkway
Pricing
CME included with membership · $195/yr
| Regular Membership (1 year) | $195/yr |
| Regular Membership (3 years) | $510 |
| International Membership (1 year) | $195/yr |
| International Membership (3 years) | $510 |
| Industry Membership (1 year) | $195/yr |
| Industry Membership (3 years) | $510 |
Collected from the provider’s public pages · source
- No reviews yet. Be the first to share yours.
Pricing
Free
Reported to ACCME by the provider
- Podcast / audio
- Credit · Up to 0.5 credits
- Commercial Support
-
Available fromNov 30, 2026
-
Last day to claim creditMay 31, 2027 8 months left
-
RxCe.com LLC Lowering the Risk: A Collaborative Approach to Statin Use
-
The Academy of Physician Associates in Cardiology (APAC) +1 Comprehensive Hyperlipidemia Care: Personalizing Lipid-Lowering Treatment Beyond Statin Therapy
-
Pri-Med Institute How I Manage Statin Reluctance and Other Challenges in Lipid Therapy
-
National Lipid Association From Cholesterol to Dyslipidemia: Translating the 2026 Multi-Society Guideline into Clinical Practice – Treatment Strategies and Targets: Podcast
-
National Lipid Association From Cholesterol to Dyslipidemia: Translating the 2026 Multi-Society Guideline into Clinical Practice – Understanding the New Dyslipidemia Paradigm: Podcast
-
National Lipid Association From Cholesterol to Dyslipidemia: Translating the 2026 Multi-Society Guideline into Clinical Practice – Risk Assessment Reimagined: Podcast
